Designed by pathologists and oncologists to create a better platform to diagnose and treat your patients.
Molecular pathology is the study of molecules in a disease state. At CellNetix, we utilize sensitive molecular tools that often confirm ambiguous diagnoses suspected by microscopic evaluation, guide therapeutic decisions and assess treatments. Molecular techniques can also assist with predicting the effectiveness of some important medications, as well as identifying specific targets in individual patients’ tumors for new therapeutic modalities “personalized medicine.”
NGS is similar in concept to traditional Sanger sequencing, where the bases of a given DNA fragment are sequentially identified through DNA re-synthesis. NGS extends this process in a massively parallel fashion across millions of reactions, rather than a limited number of DNA fragments. This significantly increases the coverage for variant calls, dramatically reduces the cost per gene per sample, and enables high throughput workflow for simultaneous screening of different types of mutations in many genes from multiple samples.
Using the Illumina Miseq platform, an individual genomic DNA (gDNA) sample is first prepared into a library of small segments with adaptors and indexes attached. Indexed samples from multiple individuals are then pooled and loaded onto a single sequencing cartridge. Each fragment of the pooled samples is attached to the solid surface through the adaptor, and then uniformly and accurately sequenced in millions of parallel reactions. All variants are interpreted by our pathologists for clinical reference using publicly available databases and medical literature, and then used to create a concise and comprehensible report that can inform timely and appropriate clinical care for cancer patients.
With SymGene79™ targeted gene panel, you can offer clients competitively priced, cutting-edge testing that isolates the 79 most actionable genes, for more relevant results, affordably delivered in weeks–not months. Learn more about SymGene here.
SymGene Focus is a collection of organ specific NGS cancer panels. This collection of validated genomic profiles are comprised of genes with compelling clinical and biological evidence as biomarkers to predict drug responses. Learn more about SymGene Focus here.
If you are not setup with an electronic interface for NGS testing, please contact your local representative or use the below requisition form and fax it to 206-215-5935 or 866-721-9697.Requisition Form
Dr. Berry is the Director of Molecular Pathology at CellNetix and leads an 18-person team of PhD scientists, informaticians and molecular technicians. Prior to joining CellNetix, she was Associate Professor at University of California at San Francisco where she performed her fellowship training in Molecular Genetic Pathology. She is also fellowship trained in cytopathology. She is available for phone and telepathology consultations.
Dr. Xu is the Molecular Pathology Technical Director of Molecular Pathology at CellNetix. Prior to joining CellNetix in 2013, she was Director of the Molecular Diagnostics Lab at Providence Sacred Heart Medical Center in Spokane, Washington, where she designed and implemented their Next Generation Sequencing program as she has done at CellNetix. Dr. Xu is board-certified in Clinical Molecular Genetics and received her medical training in Tianjin, China. She has also served as program director and training director for the ABMG Clinical Molecular Genetics fellowship program.
Dr. Keenan is board-certified in molecular genetic pathology, and anatomic and clinical pathology. He subspecializes in molecular genetic and surgical pathology. He attended medical school at the University of Colorado School of Medicine in Aurora, CO. Dr. Keenan also completed residency training in anatomic and clinical pathology from the University of California Irvine, where he served as Chief Resident from 2014 to 2015. He completed a fellowship in molecular genetic pathology from The Cleveland Clinic in Ohio and a fellowship in surgical pathology from the University of California, Los Angeles.